The European Union’s health system is at a crossroads, where decades of investment in reactive care now threaten to collapse under the weight of an unmet crisis. At the Euractiv Health Policy Conference, policymakers and advocates warned that Europe’s current model—a 80% allocation to treatment and 3–6% to prevention—is unsustainable. This imbalance isn’t just a financial issue; it’s a moral one, echoing the same systemic failures that have plagued public health for centuries. The EU’s health budget, though massive, is a microcosm of a larger problem: how to fund a world where disease is treated after it occurs, rather than preventing it.
The numbers are stark. Cardiovascular disease, the leading cause of death in the EU, accounts for 1.7 million annual deaths and a staggering €282 billion in economic costs. Experts like Birgit Beger of the European Heart Network argue that four-fifths of these cases could be avoided with existing interventions—yet they remain largely untapped. This disconnect between knowledge and action is a recurring theme in Europe’s health policy. What makes this particularly fascinating is how the EU’s obsession with treating illness has led to a paradox: the more we invest in care, the less we invest in prevention, and the more we risk breaking the system.
But the crisis isn’t just about money. It’s about the very nature of health systems. Fraser Goodwin of the European Federation of Allergy and Airways Diseases Patients’ Associations paints a bleak picture of a “polycrisis” — aging populations, chronic disease, climate change, and antimicrobial resistance all converging to strain healthcare resources. He argues that Europe’s current infrastructure, built around acute treatment, is ill-equipped to handle these overlapping crises. This is a warning for the 21st century: healthcare is no longer just about managing illness, but about shaping the future.
The solution, however, isn’t a simple shift in funding. It requires a fundamental reorientation of policy. Várhelyi’s call for a “rebalance” — prioritizing prevention over cure — is compelling, but it’s only part of the equation. The EU’s budget is limited, and national governments often prioritize immediate needs over long-term planning. Yet, the potential for systemic change lies in Brussels’ ability to act as a multiplier. By coordinating efforts across member states and leveraging WHO guidelines, Europe could pioneer a model that others might follow.
Industry leaders, too, are wary of complacency. Alexander Natz of EUCOPE warns that pharmaceutical innovation is a double-edged sword. While prevention is essential, Europe risks diverting investment to other priorities — such as geopolitical tensions or regulatory complexity — that undermine its competitiveness. This raises a critical question: can Europe balance its role as a global health leader with the demands of a fragmented political landscape?
What many people don’t realize is that this crisis isn’t unique to Europe. The same patterns play out in North America, Africa, and Asia, where healthcare systems are increasingly strained by rising chronic diseases and aging populations. But Europe’s situation is especially dire because its health budget is so heavily weighted toward treatment, creating a feedback loop where preventive measures are underfunded and ignored. This is a cautionary tale for the 21st century: the future of healthcare depends on whether societies choose to treat illness as a crisis or as a choice.
In my opinion, the EU’s struggle is emblematic of a broader cultural shift. For too long, healthcare has been viewed as a cost center, not a strategic asset. But as the polycrisis becomes more urgent, the time to rethink this paradigm is slipping away. The question isn’t whether Europe can afford its current model — it’s whether it can afford to build a system that values prevention over reaction. The answer lies not in grand gestures, but in small, persistent choices: tighter tobacco controls, healthier food environments, and early detection programs that prioritize people’s well-being over profit. Only then can Europe reclaim its role as a global health leader.
